NYSE:LCI - Lannett Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.69 -0.24 (-3.03 %)
(As of 03/22/2019 03:57 AM ET)
Previous Close$7.93
Today's Range$7.6550 - $7.96
52-Week Range$3.33 - $17.58
Volume1.05 million shs
Average Volume1.61 million shs
Market Capitalization$302.12 million
P/E Ratio2.48
Dividend YieldN/A
Beta2.48
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages. It also provides its products for various medical indications comprising cholesterol, muscle spasm, pain management, irritable bowel, antipsychosis, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, migraine, bronchospasms, and gallstone. In addition, the company manufactures active pharmaceutical ingredients. It markets its products under the Lipitor, Lioresal, Bentyl, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Concerta, Toprol-XL, Prilosec, Ditropan, Protonix, Imitrex, Brethine, and Actigall brands to generic pharmaceutical and private label distributors, drug wholesalers, chain drug retailers, mail-order pharmacies, other pharmaceutical manufacturers, managed care and health maintenance organizations, hospital buying groups, and governmental entities. The company has supply and development agreements with Jerome Stevens Pharmaceuticals, Summit Bioscience LLC, HEC Pharm Group, Andor Pharmaceuticals LLC, Dexcel Pharma, and Aralez Pharmaceuticals. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.

Receive LCI News and Ratings via Email

Sign-up to receive the latest news and ratings for LCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP51601210
Phone215-333-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$684.56 million
Cash Flow$4.3446 per share
Book Value$15.76 per share

Profitability

Net Income$28.69 million

Miscellaneous

Employees1,251
Market Cap$302.12 million
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable

Lannett (NYSE:LCI) Frequently Asked Questions

What is Lannett's stock symbol?

Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) posted its quarterly earnings data on Wednesday, February, 6th. The company reported $0.86 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.68 by $0.18. The business had revenue of $193.70 million for the quarter, compared to analysts' expectations of $162.51 million. Lannett had a negative net margin of 39.44% and a positive return on equity of 22.88%. The business's revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 earnings per share. View Lannett's Earnings History.

When is Lannett's next earnings date?

Lannett is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Lannett.

What guidance has Lannett issued on next quarter's earnings?

Lannett issued an update on its FY 2019 earnings guidance on Wednesday, February, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $615-635 million, compared to the consensus revenue estimate of $598.79 million.

What price target have analysts set for LCI?

6 Wall Street analysts have issued 1 year price objectives for Lannett's stock. Their predictions range from $8.00 to $43.00. On average, they anticipate Lannett's stock price to reach $21.8750 in the next year. This suggests a possible upside of 184.5% from the stock's current price. View Analyst Price Targets for Lannett.

What is the consensus analysts' recommendation for Lannett?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lannett.

Has Lannett been receiving favorable news coverage?

News stories about LCI stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lannett earned a news impact score of 1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the immediate future.

Are investors shorting Lannett?

Lannett saw a increase in short interest in February. As of February 15th, there was short interest totalling 17,734,164 shares, an increase of 20.4% from the January 31st total of 14,734,544 shares. Based on an average daily volume of 2,277,396 shares, the days-to-cover ratio is currently 7.8 days. Approximately 66.0% of the shares of the company are short sold. View Lannett's Current Options Chain.

Who are some of Lannett's key competitors?

What other stocks do shareholders of Lannett own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lannett investors own include Celgene (CELG), Gilead Sciences (GILD), Akorn (AKRX), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Micron Technology (MU), Ambarella (AMBA), Skechers USA (SKX), Bank of America (BAC) and Netflix (NFLX).

Who are Lannett's key executives?

Lannett's management team includes the folowing people:
  • Mr. Timothy C. Crew, CEO & Director (Age 58)
  • Mr. Martin P. Galvan, VP of Fin. & CFO (Age 67)
  • Mr. Samuel H. Israel, Gen. Counsel & Chief Legal Officer (Age 57)
  • Mr. John M. Abt, VP & Chief Quality Operations Officer (Age 54)
  • Mr. John Kozlowski, Chief of Staff & Strategy Officer (Age 47)

Who are Lannett's major shareholders?

Lannett's stock is owned by many different of institutional and retail investors. Top institutional investors include Telemus Capital LLC (20.07%), BlackRock Inc. (12.14%), Canada Pension Plan Investment Board (2.81%), Dimensional Fund Advisors LP (2.05%), Dimensional Fund Advisors LP (2.05%) and Bank of New York Mellon Corp (1.57%). Company insiders that own Lannett stock include Albert Paonessa III, Arthur P Bedrosian, David Farber, Kevin Smith, Patrick G Lepore and Timothy C Crew. View Institutional Ownership Trends for Lannett.

Which institutional investors are selling Lannett stock?

LCI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Telemus Capital LLC, CLARET ASSET MANAGEMENT Corp, Northern Trust Corp, KBC Group NV, Bank of New York Mellon Corp, Jane Street Group LLC and SG Americas Securities LLC. View Insider Buying and Selling for Lannett.

Which institutional investors are buying Lannett stock?

LCI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Canada Pension Plan Investment Board, Alambic Investment Management L.P., Two Sigma Investments LP, Prudential Financial Inc., Two Sigma Advisers LP, Martingale Asset Management L P and Norges Bank. Company insiders that have bought Lannett stock in the last two years include Albert Paonessa III, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett.

How do I buy shares of Lannett?

Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lannett's stock price today?

One share of LCI stock can currently be purchased for approximately $7.69.

How big of a company is Lannett?

Lannett has a market capitalization of $302.12 million and generates $684.56 million in revenue each year. The company earns $28.69 million in net income (profit) each year or $3.10 on an earnings per share basis. Lannett employs 1,251 workers across the globe.

What is Lannett's official website?

The official website for Lannett is http://www.lannett.com.

How can I contact Lannett?

Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at 215-333-9000.


MarketBeat Community Rating for Lannett (NYSE LCI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  413 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  738
MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: FAANG Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel